In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model

Cellular Immunology

Volumn 251, Issue 2, 2008, Pages 78-85

  Wu, Christina C N ^a   Sabet, Mojgan ^b   Hayashi, Tomoko ^a   Tawatao, Rommel ^a   Fierer, Joshua ^b,c   Carson, Dennis A ^a   Guiney, Donald G ^b   Corr, Maripat ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Research Service   (United States)

Author keywords

Anthrax; Cytokines; Lung; Phosphodiester oligonucleotide; TLR 9

Indexed keywords

ANTHRAX VACCINE; GAMMA INTERFERON; IMMUNOSTIMULATORY OLIGONUCLEOTIDE; IMMUNOSTIMULATORY OLIGONUCLEOTIDE R 10 60; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; OLIGONUCLEOTIDE; OVALBUMIN; PEPTIDE APTAMER; PS 1018; PS 1019; R 10 60; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MODEL; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; ANTHRAX; APTAMERS, NUCLEOTIDE; BACILLUS ANTHRACIS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; KINETICS; LUNG DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPORES, BACTERIAL; TOLL-LIKE RECEPTOR 9;

BACTERIA (MICROORGANISMS); MUS;

EID: 48949116091     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.04.001     Document Type: Article

References (52)

1. Creticos P.S., and Lichtenstein L.M. Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions. Arb. Paul Ehrlich Inst. Bundesamt Sera Impfstoffe Frankf. A. M. 94 (2003) 304-312 discussion 312-313.
2. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., Laframboise C., Al Adhami M.J., Khaliq Y., Seguin I., and Cameron D.W. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22 (2004) 3136-3143
3. Boggs R.T., McGraw K., Condon T., Flournoy S., Villiet P., Bennett C.F., and Monia B.P. Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7 (1997) 461-471
4. Monteith D.K., Henry S.P., Howard R.B., Flournoy S., Levin A.A., Bennett C.F., and Crooke S.T. Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des. 12 (1997) 421-432
5. Pisetsky D.S., and Reich C. Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Mol. Biol. Rep. 18 (1993) 217-221
6. Vollmer J., Janosch A., Laucht M., Ballas Z.K., Schetter C., and Krieg A.M. Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 12 (2002) 165-175
7. Dalpke A.H., Zimmermann S., Albrecht I., and Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 106 (2002) 102-112
8. Lipford G.B., Sparwasser T., Bauer M., Zimmermann S., Koch E.S., Heeg K., and Wagner H. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27 (1997) 3420-3426
9. Yuen A.R., and Sikic B.I. Clinical studies of antisense therapy in cancer. Front. Biosci. 5 (2000) D588-D593
10. Zhao Q., Matson S., Herrera C.J., Fisher E., Yu H., and Krieg A.M. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 3 (1993) 53-66
11. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
12. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73 (1999) 329-368
13. Park Y., Chang Y.S., Lee S.W., Cho S.Y., Kim Y.K., Min K.U., Kim Y.Y., Cho S.H., and Sung Y.C. The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J. Allergy Clin. Immunol. 108 (2001) 570-576
14. Wu C.C., Castro J.E., Motta M., Cottam H.B., Kyburz D., Kipps T.J., Corr M., and Carson D.A. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. Hum. Gene Ther. 14 (2003) 849-860
15. Wu C.C., Lee J., Raz E., Corr M., and Carson D.A. Necessity of oligonucleotide aggregation for toll-like receptor 9 activation. J. Biol. Chem. 279 (2004) 33071-33078
16. Hughes M.A., Green C.S., Lowchyj L., Lee G.M., Grippe V.K., Smith Jr. M.F., Huang L.Y., Harvill E.T., and Merkel T.J. MyD88-dependent signaling contributes to protection following Bacillus anthracis spore challenge of mice: implications for Toll-like receptor signaling. Infect. Immun. 73 (2005) 7535-7540
17. Kalns J., Scruggs J., Millenbaugh N., Vivekananda J., Shealy D., Eggers J., and Kiel J. TNF receptor 1, IL-1 receptor, and iNOS genetic knockout mice are not protected from anthrax infection. Biochem. Biophys. Res. Commun. 292 (2002) 41-44
18. Heine H.S., Bassett J., Miller L., Hartings J.M., Ivins B.E., Pitt M.L., Fritz D., Norris S.L., and Byrne W.R. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother. 51 (2007) 1373-1379
19. Welkos S.L., Keener T.J., and Gibbs P.H. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 51 (1986) 795-800
20. Lyons C.R., Lovchik J., Hutt J., Lipscomb M.F., Wang E., Heninger S., Berliba L., and Garrison K. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect. Immun. 72 (2004) 4801-4809
21. Loving C.L., Kennett M., Lee G.M., Grippe V.K., and Merkel T.J. Murine aerosol challenge model of anthrax. Infect. Immun. 75 (2007) 2689-2698
22. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., and Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9 (1998) 143-150
23. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S., and Raz E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18 (2000) 509-514
24. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., and Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60 (1992) 662-668
25. Klinman D.M., Xie H., Little S.F., Currie D., and Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22 (2004) 2881-2886
26. Guidi-Rontani C., Levy M., Ohayon H., and Mock M. Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol. Microbiol. 42 (2001) 931-938
27. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., Silverman G.J., Lotz M., Carson D.A., and Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273 (1996) 352-354
28. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., and Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162 (1999) 2368-2374
29. Cordoba-Rodriguez R., Fang H., Lankford C.S., and Frucht D.M. Anthrax lethal toxin rapidly activates caspase-1/ICE and induces extracellular release of interleukin (IL)-1beta and IL-18. J. Biol. Chem. 279 (2004) 20563-20566
30. Cui X., Li Y., Li X., Haley M., Moayeri M., Fitz Y., Leppla S.H., and Eichacker P.Q. Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival. J. Infect. Dis. 193 (2006) 829-840
31. Duverger A., Jackson R.J., van Ginkel F.W., Fischer R., Tafaro A., Leppla S.H., Fujihashi K., Kiyono H., McGhee J.R., and Boyaka P.N. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J. Immunol. 176 (2006) 1776-1783
32. Hanna P.C., Acosta D., and Collier R.J. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA 90 (1993) 10198-10201
33. Popov S.G., Popova T.G., Grene E., Klotz F., Cardwell J., Bradburne C., Jama Y., Maland M., Wells J., Nalca A., Voss T., Bailey C., and Alibek K. Systemic cytokine response in murine anthrax. Cell Microbiol. 6 (2004) 225-233
34. Wong P.M. Hypothesis: Ran GTPase-based potential therapeutic interventions against lethal microbial infections. Sci. World J. 2 (2002) 684-689
35. Hnatowich D.J., Mardirossian G., Fogarasi M., Sano T., Smith C.L., Cantor C.R., Rusckowski M., and Winnard Jr. P. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice. J. Pharmacol. Exp. Ther. 276 (1996) 326-334
36. Cossum P.A., Sasmor H., Dellinger D., Truong L., Cummins L., Owens S.R., Markham P.M., Shea J.P., and Crooke S. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267 (1993) 1181-1190
37. Geary R.S., Yu R.Z., and Levin A.A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2 (2001) 562-573
38. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., and McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170 (2003) 5636-5643
39. Brey R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 57 (2005) 1266-1292
40. Gu M.L., Leppla S.H., and Klinman D.M. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17 (1999) 340-344
41. Hahn U.K., Aichler M., Boehm R., and Beyer W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine 24 (2006) 4595-4597
42. Hahn U.K., Alex M., Czerny C.P., Bohm R., and Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. Int. J. Med. Microbiol. 294 (2004) 35-44
43. Krieg A.M. Antiinfective applications of toll-like receptor 9 agonists. Proc. Am. Thorac. Soc. 4 (2007) 289-294
44. Klinman D.M. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. Expert Rev. Vaccines 5 (2006) 365-369
45. Xie H., Gursel I., Ivins B.E., Singh M., O'Hagan D.T., Ulmer J.B., and Klinman D.M. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73 (2005) 828-833
46. Deng J.C., Moore T.A., Newstead M.W., Zeng X., Krieg A.M., and Standiford T.J. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J. Immunol. 173 (2004) 5148-5155
47. Hayashi T., Rao S.P., Takabayashi K., Van Uden J.H., Kornbluth R.S., Baird S.M., Taylor M.W., Carson D.A., Catanzaro A., and Raz E. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun. 69 (2001) 6156-6164
48. Ito S., Ishii K.J., Gursel M., Shirotra H., Ihata A., and Klinman D.M. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J. Immunol. 174 (2005) 777-782
49. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., and Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 27 (2004) 460-471
50. Sabet M., Cottam H.B., and Guiney D.G. Modulation of cytokine production and enhancement of cell viability by TLR7 and TLR9 ligands during anthrax infection of macrophages. FEMS Immunol. Med. Microbiol. 47 (2006) 369-379
51. Amlie-Lefond C., Paz D.A., Connelly M.P., Huffnagle G.B., Whelan N.T., and Whelan H.T. Innate immunity for biodefense: a strategy whose time has come. J. Allergy Clin. Immunol. 116 (2005) 1334-1342
52. Wu C.C., Hayashi T., Takabayashi K., Sabet M., Smee D.F., Guiney D.D., Cottam H.B., and Carson D.A. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl. Acad. Sci. USA 104 (2007) 3990-3995